The local medical sector is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for addressing obesity. This therapy https://adsbookmark.com/story21884891/retatrutide-australia-australia-a-emerging-hope-for-weight-loss